B-type natriuretic levels in critically ill patients: critically misleading?

Department of Medicine, Baylor College of Medicine, 6620 Main Street, 11A,08, Houston, TX 77030, USA.
Critical care (London, England) (Impact Factor: 4.48). 08/2009; 13(4):163. DOI: 10.1186/cc7938
Source: PubMed


Although B-type natriuretic peptide (BNP) has been used for the diagnosis of congestive heart failure in many clinical settings, its diagnostic role in critically ill patients remains uncertain. The body of literature suggests that BNP and N-terminal pro-BNP levels are not useful for the diagnosis of systolic or diastolic heart failure in the critically ill, including in patients with brain hemorrhage, due to poor specificity. However, these cardiac peptides may have a more promising prognostic role in this patient population.

Download full-text


Available from: Hisham Dokainish, Feb 03, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain natriuretic peptide (BNP) is important in the diagnosis and management of heart failure (HF). Sometimes, very high BNP levels encountered in clinical settings seem to be out of proportion to the severity of HF. The authors retrospectively identified 113 patients with 129 admissions with a BNP value >3000 pg/mL regardless of diagnosis. The data set was analyzed using the Student t test and bivariate analysis. Fewer than half of patients were admitted for HF. In 14 patients (10.9%), no signs of HF were found. The BNP level of those with and without HF was similar. There was no difference in BNP level in patients with and without systolic dysfunction or renal dysfunction and between different age groups. Extreme values of BNP do not necessarily correlate with the presence of HF, cardiomyopathy, or kidney dysfunction. When the magnitude of BNP elevation is very high, its clinical significance is limited.
    Preview · Article · Sep 2010 · Congestive Heart Failure